237 related articles for article (PubMed ID: 32324178)
1. Two drugs for sickle cell disease.
Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
[No Abstract] [Full Text] [Related]
2. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
3. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
Estepp JH
Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
[No Abstract] [Full Text] [Related]
4. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
5. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
7. Two New Drugs for Sickle Cell Disease.
Aschenbrenner DS
Am J Nurs; 2020 Mar; 120(3):24. PubMed ID: 32079792
[No Abstract] [Full Text] [Related]
8. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
9. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
10. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
12. Casgevy and Lyfgenia: Two gene therapies for sickle cell disease.
Med Lett Drugs Ther; 2024 Jan; 66(1694):9-10. PubMed ID: 38212256
[No Abstract] [Full Text] [Related]
13. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Ershler WB; Holbrook ME
Transfusion; 2020 Dec; 60(12):3066-3067. PubMed ID: 32815179
[No Abstract] [Full Text] [Related]
14. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
15. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Çanak B; Eşkazan AE
Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
[No Abstract] [Full Text] [Related]
16. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
Chen M; Hankins JS; Zhang M; Ataga KI
Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
[TBL] [Abstract][Full Text] [Related]
18. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?
Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD
Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770
[No Abstract] [Full Text] [Related]
19. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
20. Sickle cell drug raises hopes and doubts.
Wadman M
Science; 2019 Sep; 365(6459):1235. PubMed ID: 31604221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
